Bio-Gene Technology Limited (ASX:BGT)
Australia · Delayed Price · Currency is AUD 0.0170
0.00 (0.00%)
Jul 15, 2026, 9:59 AM AEST
Bio-Gene Technology Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 18.32K | -130.91K | -87.72% |
| Jun 30, 2023 | 149.23K | -296.49K | -66.52% |
| Jun 30, 2022 | 445.73K | 383.12K | 611.91% |
| Jun 30, 2021 | 62.61K | -60.19K | -49.01% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tissue Repair | 3.38M |
| Acrux | 2.81M |
| Cynata Therapeutics | 1.69M |
| Cambium Bio | 668.79K |
| Anatara Lifesciences | 623.76K |
| AdAlta | 608.07K |
| ReNerve | 333.21K |
| Invex Therapeutics | 229.08K |